

wherein;


$R_6 = S$ or O

R_3 is selected from the group consisting of $C_1 - C_8$ linear or branched alkyl; $C_2 - C_8$ linear or branched alkene; $C_2 - C_8$ linear or branched alkyne; C_{3-8} cycloalkyl; Q ; and K ;

R_8 is selected from the group consisting of $C_1 - C_8$ linear or branched alkyl; $C_2 - C_8$ linear or branched alkene; $C_2 - C_8$ linear or branched alkyne; C_{3-8} cycloalkyl; Q ; and K ;

wherein

Q has the general formula:



wherein;

$n = 0$ or 1 ;


$Z =$ a bond, CH_2 , NH , O or S ;

A and B can form a ring by adding 1-3 CH_2 groups when $Z = CH_2$, NH , O or S ; and

A and B are not in a ring when $Z =$ a bond, wherein A and B are independently selected from the group consisting of hydrogen; halogen; $C_1 - C_8$ alkyl; $C_1 - C_8$ alkoxy; $C_3 - C_8$ cycloalkyl; $C_3 - C_8$ cycloalkoxy; hydroxy; phenyl; benzyl; and benzyloxy; wherein said phenyl, benzyl and benzyloxy are optionally substituted with halogen, $C_1 - C_8$ alkyl, $C_1 - C_8$ alkoxy, $C_3 - C_8$ cycloalkyl, $C_3 - C_8$ cycloalkoxy and hydroxy;

A!
Cont'd
Sub B!
Cont'd

K has the general formula:



wherein;

$n = 0$ or 1 ;

L and M are independently selected from the group consisting of hydrogen and methyl;

W is selected from the group consisting of Q; hydroxy; benzyloxy optionally substituted with halogen, $\text{C}_1 - \text{C}_8$ alkyl, $\text{C}_1 - \text{C}_8$ alkoxy, $\text{C}_3 - \text{C}_8$ cycloalkyl, $\text{C}_3 - \text{C}_8$ cycloalkoxy and hydroxy; aryl; heteroaryl; and a heterocyclic ring;

provided that when R_3 is methyl, R_8 is not hydrogen;

and pharmaceutically acceptable salts thereof;

and at least one pharmaceutically acceptable excipient; said composition in the form of a solid dosage form.

2. (Amended) The pharmaceutical composition of claim 1 wherein R_3 is benzyl.

3. (Amended) The pharmaceutical composition of claim 1 wherein R_3 is benzyl substituted with an alkoxy and a cycloalkoxy group.

5. (Amended) The pharmaceutical composition of claim 1, wherein said compound is selected from the group consisting of:

*A2
Intel*
*Sub B2
Cont*

3-methyl-hypoxanthine;
3-butyl-hypoxanthine;
3-butyl-thiohypoxanthine;
3-ethyl-hypoxanthine;
3-ethyl-thiohypoxanthine;
3,8-diethyl-hypoxanthine;
3,8-diethyl-thiohypoxanthine;
3-ethyl-8-cyclopropyl-hypoxanthine;
3-ethyl-8-cyclopropyl-thiohypoxanthine;
3-propyl-hypoxanthine;
3-hexyl-hypoxanthine;
3-hexyl-thiohypoxanthine;
3-benzyl-hypoxanthine;
3-benzyl-thiohypoxanthine;
3-(4-methyl-butyl)-hypoxanthine;
3-(4-methyl-butyl)-thiohypoxanthine;
3-(2-methyl-butyl)-hypoxanthine;
3-(2-methyl-butyl)-thiohypoxanthine;
3-(3-cyclopentyloxy-4-methoxy-benzyl)-hypoxanthine;
3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-hydroxy-1-methyl-ethyl)-hypoxanthine;
3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-methyl-ethylene)-hypoxanthine;
3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-benzyloxy-1-methyl-ethyl)-hypoxanthine;
3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(benzyloxymethyl)-hypoxanthine;
3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;

3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-(4-methoxybenzyloxy)-1-methyl-ethyl)-hypoxanthine;

3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-(4-fluorobenzyloxy)-1-methyl-ethyl)-hypoxanthine;

3-(3-benzyloxy-4-methoxy-benzyl)-8-(1-benzyloxy-1-methyl-ethyl)-hypoxanthine;

3-(3-4-dimethoxy-benzyl)-8-(1-benzyloxy-1-methyl-ethyl)-hypoxanthine;

3-(3-benzyloxy-4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;

3-(3-hydroxy-4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;

3-(3-4-dimethoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;

3-(1,3-benzdioxole-5-methyl)-8-(1-methyl-ethyl)-hypoxanthine;

3-(4-chloro-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;

3-(3-chloro-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;

3-(4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;


3-(3-4-dimethoxy-benzyl)-8-(1-(4-fluorobenzyloxy)-1-methyl-ethyl)-hypoxanthine;

and pharmaceutically acceptable salts thereof.

Please add the following new claims:

16. (New) The pharmaceutical composition of claim 1, wherein said solid dosage form is selected from the group consisting of tablets, gelcaps, capsules, caplets, granules, lozenges and bulk powders.

17. (New) A pharmaceutical composition comprising a compound of the formula:



wherein;


$R_6 = S$ or O

R_3 is selected from the group consisting of $C_1 - C_8$ linear or branched alkyl; $C_2 - C_8$ linear or branched alkene; $C_2 - C_8$ linear or branched alkyne; C_{3-8} cycloalkyl; Q ; and K ;

R_8 is selected from the group consisting of $C_1 - C_8$ linear or branched alkyl; $C_2 - C_8$ linear or branched alkene; $C_2 - C_8$ linear or branched alkyne; C_{3-8} cycloalkyl; Q ; and K ;

wherein

Q has the general formula:



wherein;

$n = 0$ or 1 ;


$Z =$ a bond, CH_2 , NH , O or S ;

A and B can form a ring by adding $1-3 CH_2$ groups when $Z = CH_2$, NH , O or S ; and

A and B are not in a ring when $Z =$ a bond, wherein A and B are independently selected

from the group consisting of hydrogen; halogen; C₁ – C₈ alkyl; C₁ – C₈ alkoxy; C₃ – C₈ cycloalkyl; C₃ – C₈ cycloalkoxy; hydroxy; phenyl; benzyl; and benzyloxy; wherein said phenyl, benzyl and benzyloxy are optionally substituted with halogen, C₁ – C₈ alkyl, C₁ – C₈ alkoxy, C₃ – C₈ cycloalkyl, C₃ – C₈ cycloalkoxy and hydroxy;

K has the general formula:



wherein;

n = 0 or 1;

L and M are independently selected from the group consisting of hydrogen and methyl;

W is selected from the group consisting of Q; hydroxy; benzyloxy optionally substituted with halogen, C₁ – C₈ alkyl, C₁ – C₈ alkoxy, C₃ – C₈ cycloalkyl, C₃ – C₈ cycloalkoxy and hydroxy; aryl; heteroaryl; and a heterocyclic ring;

provided that when R₃ is methyl, R₈ is not hydrogen;

and pharmaceutically acceptable salts thereof, said composition in the form of a liquid dosage form selected from the group consisting of emulsions and suspensions.

18. (New) The pharmaceutical composition of claim 17, wherein R₃ is benzyl.

19. (New) The pharmaceutical composition of claim 17, wherein R₃ is benzyl substituted with an alkoxy and a cycloalkoxy group.

20. (New) The pharmaceutical composition of claim 17, wherein said compound is selected from the group consisting of:

- A3*
Contd
- Sub B4*
- 3-methyl-hypoxanthine;
 - 3-butyl-hypoxanthine;
 - 3-butyl-thiohypoxanthine;
 - 3-ethyl-hypoxanthine;
 - 3-ethyl-thiohypoxanthine;
 - 3,8-diethyl-hypoxanthine;
 - 3,8-diethyl-thiohypoxanthine;
 - 3-ethyl-8-cyclopropyl-hypoxanthine;
 - 3-ethyl-8-cyclopropyl-thiohypoxanthine;
 - 3-propyl-hypoxanthine;
 - 3-hexyl-hypoxanthine;
 - 3-hexyl-thiohypoxanthine;
 - 3-benzyl-hypoxanthine;
 - 3-benzyl-thiohypoxanthine;
 - 3-(4-methyl-butyl)-hypoxanthine;
 - 3-(4-methyl-butyl)-thiohypoxanthine;
 - 3-(2-methyl-butyl)-hypoxanthine;
 - 3-(2-methyl-butyl)-thiohypoxanthine;
 - 3-(3-cyclopentyloxy-4-methoxy-benzyl)-hypoxanthine;
 - 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-hydroxy-1-methyl-ethyl)-hypoxanthine;
 - 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-methyl-ethylene)-hypoxanthine;
 - 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-benzoyloxy-1-methyl-ethyl)-hypoxanthine;

3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(benzyloxymethyl)-hypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-(4-methoxybenzyloxy)-1-methyl-ethyl)-
 hypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-(4-fluorobenzyloxy)-1-methyl-ethyl)-
 hypoxanthine;
 3-(3-benzyloxy-4-methoxy-benzyl)-8-(1-benzyloxy-1-methyl-ethyl)-hypoxanthine;
 3-(3-4-dimethoxy-benzyl)-8-(1-benzyloxy-1-methyl-ethyl)-hypoxanthine;
 3-(3-benzyloxy-4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(3-hydroxy-4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(3-4-dimethoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(1,3-benzdioxole-5-methyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(4-chloro-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(3-chloro-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(3-4-dimethoxy-benzyl)-8-(1-(4-fluorobenzyloxy)-1-methyl-ethyl)-hypoxanthine;
 and pharmaceutically acceptable salts thereof.

REMARKS

Claims 1-3 and 5 are pending. Claims 4 and 6-15 are withdrawn from consideration as being directed to a nonelected invention. Claims 1-3 and 5 have been amended and claims 16-20 have been added. The attached pages are captioned "Version of Amendments With Markings to Show Changes Made." It is respectfully submitted that no new matter has been added by virtue of this amendment.